COVID-19 Experiences in the SELF Cohort
NCT05369611 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1668
Last updated 2026-05-22
Summary
Background:
COVID-19 affected African Americans more than Whites. African Americans, especially women, have had higher rates of COVID-19 infections compared to Whites. They are also more likely to go to the hospital or die of this disease. Many researchers who looked into these issues lacked background data on the people they studied. SELF is a 10-year study of fibroids in African American women aged 23-35. Researchers already have a lot of data on these women. Asking how COVID-19 affected them can add context other studies lack.
Objective:
To describe the impact of the COVID-19 pandemic on young African American women and their families.
Eligibility:
Participants must be enrolled in SELF (Study of Environment, Lifestyle, and Fibroids).
Design:
Researchers will invite all women enrolled in SELF to participate in this natural history study.
Participants will complete one questionnaire. They will answer the questions online. They may also choose to get a paper copy sent by mail. The survey will take no more than 15-20 minutes.
All questions will relate to COVID-19. Participants will be asked if they had COVID-19. They will be asked if family, friends, or members of their community did. They will answer questions about their vaccine status and access to health care services.
Participants will also answer questions about how the pandemic affected their lives. They will be asked about their job and if finding childcare was a challenge. They will be asked about money problems and how they coped. They will be asked about sleep problems and emotional distress.
Participants will get a $30 gift card after they finish the survey.
Conditions
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Principal Investigators
-
Chandra L Jackson, Ph.D. · National Institute of Environmental Health Sciences (NIEHS)
Eligibility
- Min Age
- 23 Years
- Max Age
- 35 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-06-17
- Primary Completion
- 2026-12-30
- Completion
- 2026-12-30
Countries
- United States
Study Locations
More Related Trials
-
An Expanded Safety Study of Dapivirine Gel 4759 in Africa
NCT00917891 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Optical Imaging and User Perception Study of Vaginal Gel
NCT01716000 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test
NCT04437940 ·Status: COMPLETED
-
A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
NCT00303576 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
NCT02272231 ·Status: COMPLETED
-
Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects
NCT01020877 ·Status: COMPLETED ·Phase: PHASE1
-
ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study
NCT03082690 ·Status: COMPLETED ·Phase: PHASE1
-
Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis
NCT02185456 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety Study of MucoCept-CVN
NCT07181486 ·Status: RECRUITING ·Phase: PHASE1
-
Vaginal Microbiome Research Consortium for Africa
NCT06662747 ·Status: RECRUITING
-
To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women
NCT02862171 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study to Treat Bacterial Vaginosis
NCT01621399 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of SAVVY Vaginal Gel and HIV in Nigeria
NCT00130078 ·Status: UNKNOWN ·Phase: PHASE3
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308007 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
NCT01539226 ·Status: COMPLETED ·Phase: NA
-
A Study of Nonoxynol-9 (N-9) and HIV Infection
NCT00000926 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
NCT00799058 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
NCT02818582 ·Status: COMPLETED ·Phase: PHASE2
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308033 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Controlled Trial of Treatment of Male Partners of Women With BV
NCT02209519 ·Status: COMPLETED ·Phase: PHASE3
-
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
NCT00074425 ·Status: COMPLETED ·Phase: PHASE2
-
Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females
NCT00706368 ·Status: UNKNOWN ·Phase: NA
-
FB101 Intervention in Women Screened to Have Vaginal Dysbiosis
NCT05114031 ·Status: COMPLETED ·Phase: NA
-
Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution
NCT00260767 ·Status: UNKNOWN ·Phase: PHASE1
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308046 ·Status: COMPLETED ·Phase: PHASE3